Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Can-Fite BioPharma ( (CANF) ) is now available.
On April 30, 2026, Can-Fite BioPharma reported positive Phase 2a data for its A3 adenosine receptor agonist namodenoson in advanced pancreatic cancer, showing preliminary clinical activity and durable disease stabilization in a heavily pretreated population. More than 30% of evaluable patients achieved stable disease, 35% remain on therapy, one patient has been treated for over 16 months, and the study met its primary safety endpoint with a favorable tolerability profile and no new safety signals.
The open-label trial enrolled 20 evaluable patients whose disease had progressed on at least first-line therapy or who refused standard treatment, with all receiving oral namodenoson twice daily in 28-day cycles. The data reinforce Can-Fite’s positioning in difficult-to-treat oncology indications, support continued development of namodenoson in pancreatic cancer alongside its existing orphan and fast-track designations in other cancers, and set the stage for upcoming progression-free and overall survival readouts expected to be presented at a clinical conference in the coming months.
The most recent analyst rating on (CANF) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technical signals (price below key moving averages with negative MACD). Low leverage provides some risk mitigation, but valuation is not supportive given losses and no dividend data.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary small molecule drugs targeting multi-billion-dollar markets in cancer, liver and inflammatory diseases. Its lead candidates include piclidenoson for psoriasis, namodenoson for hepatocellular carcinoma, MASH and pancreatic cancer, and CF602 for erectile dysfunction, all supported by an extensive safety database across more than 1,600 patients.
Average Trading Volume: 698,536
Technical Sentiment Signal: Sell
Current Market Cap: $6.48M
For a thorough assessment of CANF stock, go to TipRanks’ Stock Analysis page.